news

PDA revises report on glass container manufacturing

7
SHARES

Parenteral Drug Association (PDA)’s 2023 technical report on nonconformities in glass containers during pharmaceutical manufacturing represents best practices for identification and classification.

PDA revises report on glass container manufacturing

Revised for 2023, the Parenteral Drug Association (PDA) has published an update to its Technical Report No. 43: Identification and Classification of Nonconformities in Moulded and Tubular Glass Containers for Pharmaceutical Manufacturing.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The long-awaited PDA TR 43 report provides an approach to a quality decision-making process and represents best practices for the identification and classification of visual nonconformities for (empty) glass containers as pharmaceutical product packaging.

Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types.

According the PDA, the standardised quality criteria in TR 43 are intended as a guidance overview for container manufacturers and for incoming container acceptance inspection at pharmaceutical companies. These guidelines are not intended to establish mandatory standards but instead to complement existing guidelines, standards and referenced materials.

Included in the TR 43 report are five detailed and updated lexicons, which visually illustrate glass nonconformities:

  • One for moulded glass bottles and vials
  • Four for tubular glass vials, ampoules, cartridges, and syringes (see Section 8.0 (Appendix).

In addition, defects specific to ready-to-use containers and their categorisation are included for use as applicable.

Within TR 43, PDA emphasises the importance of consulting with the appropriate regulatory authorities when agreeing on the strategies employed for identification and classification of visual nonconformities of glass containers. Specifically, the document covers the development process of glass containers for pharmaceutical products, glass container sampling as well as definition of lots.

In February 2023, the PDA released its Technical Report 90: Contamination Control Strategy Development in Pharmaceutical Manufacturing.

Share via
Share via